CSWM
KROS icon

Cassady Schiller Wealth Management’s Keros Therapeutics KROS Stock Holding History

Cassady Schiller Wealth Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.19K Buy
+75
New +$3.9K ﹤0.01% 741

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Cassady Schiller Wealth Management's KROS Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Keros Therapeutics (KROS) in Q4 2024: 75 shares worth $1.19K. The stake represents ﹤0.01% of the portfolio and ranks #741 among its holdings.

161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • Cassady Schiller Wealth Management held 75 shares of Keros Therapeutics worth $1.19K as of Q4 2024.
  • Keros Therapeutics was a new Cassady Schiller Wealth Management position in Q4 2024.
  • Keros Therapeutics made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #741 holding.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.